23rd August 2019
Joining French SME Aenitis as a guest of EIT Health at the meeting in Dublin
The Estonian SME Self-diagnostics was one of two particularly promising European start-ups that EIT Health chose to invite to the Medtech Strategist Forum, which unites more than 450 leading key decision-makers and investors in Dublin, Ireland during 9-11 April 2019.
SelfDiagnostics is a medtech company, headquartered in Tallinn, Estonia, that produces medical self-tests. The company’s NINAAT (Non-Instrumented Nucleic Acid Amplification) molecular diagnostics innovations, using PCR (polymerase chain reaction) technology, can be used for varying diagnostics purposes, such as pharmaceuticals, food, veterinary, agriculture, military, or cosmetics. The first product is a multi-test for sexually transmitted diseases.
Selected by EIT Health Investor Network
SelfDiagnostics was joined by the French SME Aenitis at the investor’s forum. They were selected from a wide range of promising European start-ups by EIT Health Investor Network programme, and EIT Health funded their entrance ticket to the forum, valued at €2 000.
The Investor Network programme is an EIT Health Accelerator programme to enable international co-investments of venture capitalists, business angels networks and associations, family offices etc. to start-ups selected by EIT Health.
About the MedTech Strategist Forum
The MedTech Strategist Forum is recognised as the leading medical technology investment forum in Europe. It provides the opportunity to companies to meet with large European investors and pitch their business ideas to them, to attract possible new investments or discuss IPO opportunities. EIT Health is a supporter of the MedTech Strategist summit and is also represented at the top-tier event.
Find out more
EIT Health joins “Seeds of Bravery” Consortium
Discover how we will support Ukrainian start-ups.
EIT Health renews strategic alliance with HIMSS Partner Innovation Exchange (PIE) Initiative
Read more about the partnership
EIT Health Flagships Call 2024 open for applications
First cut-off 28 February